Merck Talks About Its Pipeline Post-Singulair
This article was originally published in The Pink Sheet Daily
Executive Summary
With its blockbuster asthma drug Singulair going off-patent at the end of the year, Merck is looking to a few key drugs to fill the revenue gap in the coming years, said the company at a recent Deutsche Bank Healthcare conference.